”We have to create respect”

The Danish gene analysis company, Exiqon, is still struggling to secure the same level of growth rates in the US as they see in Europe. But following a difficult period things are looking up. The top line should be boosted, says CEO Lars Kongsbak, and new products play a crucial role in this regard.

It is often said that it can be extremely difficult to secure growth outside of ones home country, but the listed, Danish company Exiqon is living prove that it can be done. The company, which is still in the red but close to breaking even, generates between 97 and 98 % of its turnover outside of Denmark.

A rise in European turnover of 47 % in Q1 2013 and significant growth in an American market, which is otherwise under a lot of pressure, gives cause for great optimism for the future for CEO Lars Kongsbak.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier